IRIS
ANGELICO, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 91.149
AS - Asia 9.084
EU - Europa 7.096
SA - Sud America 1.181
AF - Africa 116
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 16
Totale 108.659
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 90.934
SG - Singapore 4.293
CN - Cina 2.017
UA - Ucraina 1.223
DE - Germania 1.112
RU - Federazione Russa 1.009
BR - Brasile 985
HK - Hong Kong 898
IE - Irlanda 765
IT - Italia 706
VN - Vietnam 640
SE - Svezia 486
FI - Finlandia 473
FR - Francia 461
KR - Corea 340
GB - Regno Unito 333
PL - Polonia 229
BD - Bangladesh 193
JP - Giappone 171
IN - India 160
CA - Canada 112
AR - Argentina 62
NL - Olanda 60
MX - Messico 59
ID - Indonesia 46
AT - Austria 43
IQ - Iraq 43
BE - Belgio 42
TR - Turchia 42
ZA - Sudafrica 38
ES - Italia 36
EC - Ecuador 35
PK - Pakistan 29
CZ - Repubblica Ceca 27
CO - Colombia 26
CL - Cile 21
UZ - Uzbekistan 19
VE - Venezuela 19
AE - Emirati Arabi Uniti 17
EG - Egitto 17
IL - Israele 17
RO - Romania 17
AU - Australia 14
MY - Malesia 14
NP - Nepal 13
PY - Paraguay 13
SA - Arabia Saudita 12
CH - Svizzera 11
JO - Giordania 11
TN - Tunisia 11
IR - Iran 10
MA - Marocco 10
EU - Europa 9
JM - Giamaica 9
KG - Kirghizistan 9
LT - Lituania 9
PE - Perù 9
TH - Thailandia 9
DZ - Algeria 8
ET - Etiopia 8
KZ - Kazakistan 8
TW - Taiwan 8
UY - Uruguay 8
AZ - Azerbaigian 7
MD - Moldavia 7
PH - Filippine 7
A2 - ???statistics.table.value.countryCode.A2??? 6
LK - Sri Lanka 6
OM - Oman 6
AL - Albania 5
GT - Guatemala 5
HN - Honduras 5
PT - Portogallo 5
SY - Repubblica araba siriana 5
AO - Angola 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
GR - Grecia 4
HR - Croazia 4
KE - Kenya 4
KW - Kuwait 4
LB - Libano 4
MN - Mongolia 4
TM - Turkmenistan 4
TT - Trinidad e Tobago 4
BG - Bulgaria 3
BH - Bahrain 3
BO - Bolivia 3
DM - Dominica 3
HU - Ungheria 3
NG - Nigeria 3
NI - Nicaragua 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
SN - Senegal 3
SV - El Salvador 3
AM - Armenia 2
BB - Barbados 2
BY - Bielorussia 2
Totale 108.618
Salva come PNG Salva come JPEG
Città #
Woodbridge 27.063
Wilmington 23.498
Houston 21.581
Fairfield 2.714
Singapore 2.045
Ann Arbor 1.967
Ashburn 1.484
Jacksonville 1.134
Seattle 1.107
Chandler 1.075
San Jose 916
Cambridge 909
Hong Kong 885
Beijing 752
Dublin 745
Medford 574
New York 517
Dearborn 515
Santa Clara 363
The Dalles 283
Lawrence 266
Rome 254
Helsinki 220
Los Angeles 213
Zhengzhou 203
Mülheim 190
Ho Chi Minh City 188
Kraków 174
Hanoi 167
Lauterbourg 153
Buffalo 150
Moscow 146
Council Bluffs 145
Hangzhou 138
San Diego 137
Tokyo 131
Menlo Park 121
São Paulo 106
Milan 94
Dallas 80
Orem 74
Shanghai 64
Chicago 57
Munich 56
Palo Alto 53
London 52
University Park 52
Chennai 47
Frankfurt am Main 47
Warsaw 47
Jersey City 46
Mountain View 46
Phoenix 45
Hefei 42
San Francisco 42
Norwalk 41
Boardman 40
Falls Church 40
Atlanta 39
Columbus 39
Nuremberg 39
Redwood City 38
Guangzhou 36
San Mateo 36
Brussels 35
Nanjing 35
Denver 33
Verona 33
Detroit 31
Stockholm 31
Brooklyn 30
Johannesburg 29
Manchester 29
Montreal 29
Redondo Beach 29
Toronto 26
Rio de Janeiro 24
Kunming 23
Haiphong 22
Seoul 22
Mexico City 21
Indiana 20
Amsterdam 19
Jakarta 18
Mumbai 17
Vienna 17
Baghdad 16
Belo Horizonte 16
Jinan 16
North Bergen 16
Paris 16
Poplar 16
Tashkent 16
Biên Hòa 15
Curitiba 15
Da Nang 15
Dhaka 15
Nanchang 15
Saint Petersburg 15
Ankara 13
Totale 95.309
Salva come PNG Salva come JPEG
Nome #
Crusted scabies in a liver transplant patient mimicking rupioid psoriasis 1.396
Hepatitis C reinfection after liver transplantation in relation to virus genotype 610
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 597
Boceprevir for untreated chronic HCV genotype 1 infection. 595
Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression 580
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 577
Tauroursodeoxycholate reduces ischemic damage in human allografts: a biochemical and ultrastructural study 554
Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. 529
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 527
Transport, utilization and biliary secretion of lysophosphatidylcholine in the rat liver 518
Recurrence of insulin resistant metabolic syndrome following liver transplantation 508
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 508
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. 506
Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization 504
Cyclosporine A versus tacrolimus monotherapy. Comparison on bile lipids in the first 3 months after liver transplant in humans 502
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence 499
Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C 494
Hepatitis C virus recurrence and immunosuppression-free state after liver transplantation. 492
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 490
Operational tolerance in clinical liver transplantation: emerging developments. 489
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 489
A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: The TT4 randomized trial 488
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 487
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 487
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 486
Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo. 483
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 482
Glycogen storage disease type Ia and VI associated with hepatocellular carcinoma: Two case reports 482
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 481
Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers 476
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 476
Primary yolk sac tumor of the liver: incidental finding in a patient transplanted for hepatocellular carcinoma 475
A randomized controlled trial of amantadine plus interferon-alpha 2a vs. interferon-alpha 2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha 2a monotherapy 474
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 474
Lamellar bodies coexist with vesicles and micelles in human gallbladder bile. Ursodeoxycholic acid prevents cholesterol crystal nucleation by increasing biliary lamellae 473
Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease 471
Ab initio calcineurin inhibitor-based monotherapy immunosuppression after liver transplantation reduces the risk for Pneumocystis jirovecii pneumonia. 471
Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting. 469
Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders 466
Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients 466
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 465
Taurohyodeoxycholate- and tauroursodeoxycholate-induced hypercholeresis is augmented in bile duct ligated rats 464
Liver contrast enhanced ultrasound perfusion imaging in the evaluation of chronic hepatitis C fibrosis: preliminary results 463
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 462
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late 462
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 461
596 460
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 459
Interposition of the right colic angle between the liver and thoracic wall: an unusual cause of massive rectal bleeding following percutaneous biopsy in a liver transplant recipient. 458
Activation of the IGF1 system characterizes cholangiocyte survival during progression of primary biliary cirrhosis 457
Leptin attenuates ischemia-reperfusion injury in the rat liver. 457
Comment on the PROVE1 and PROVE2 clinical trials: "I was taking a picture of Rapid Virological Response with telaprevir, but the background is unfocused!". 456
Assembly of biliary lipids in native hepatic bile after orthotopic liver transplantation: a biochemical and ultra-structural study in humans 454
In vivo, high field, 3-Tesla H MR spectroscopic asessment of liver in fibrosis in HCV-correlated chronic liver disease Valutazione in vivo della fibrosi epatica in corso di epatopatia cronica HCV con spettroscopia H-RM 3T 454
Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients 454
Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort 454
Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha 453
Percutaneous laser ablation of hepatocellular carcinoma in patients with liver cirrhosis awaiting liver transplantation. 453
A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation 453
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study 451
Extended HBV vaccination in liver transplant recipients for HBV-related cirrhosis: report of two successful cases. 450
Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension 449
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 448
Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response 447
N-ethyl-tauroursodeoxycholic acid, a novel deconjugation-resistant bile salt analogue: effects of acute feeding in the rat 447
Liver elasticity in NASH patients evaluated with real-time elastography (RTE). 447
Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting 446
Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study 446
Pitfalls in the reporting of upper endoscopy features in cirrhotic patients 446
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 444
A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B 444
Complete hbv prophylaxis withdrawal in HBsAg-positive liver transplant recipients after long-term minimal immunosuppression 444
Quasielastic light scattering evidence for vesicular secretion of biliary lipids 441
Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. 440
Effect of glucose and/or branched chain amino acid infusion on plasma amino acid imbalance in chronic liver failure 439
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 439
Interposition of the right colic angle between the liver and thoracic wall: An unusual cause of massive rectal bleeding following percutaneous biopsy in a liver transplant recipient 438
Dissolution of human cholesterol gallstones in bile salt/lecithin mixtures: effect of bile salt hydrophobicity and various pHs 438
High performance liquid chromatographic analysis of molecular species of phosphatidylcholine--development of quantitative assay and its application to human bile 438
Retrospective analysis of 30 patients who underwent liver transplantation without use of steroids 437
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C 437
Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C 436
TUDCA prevents cholestasis and canalicular damage induced by ischemia-reperfusion injury in the rat, modulating PKC alpha-ezrin pathway 435
A survey on mortality from non-variceal upper gastrointestinal bleeding: Is the emergency referral system adequate? 434
Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation 434
Sequential changes in serum and biliary bile acids after liver transplantation 433
Liver transplantation for end-stage liver disease related to viral hepatitis 432
Extended double-dosage HBV vaccination after liver transplantation is ineffective, in the absence of lamivudine and prior wash-out of human Hepatitis B immunoglobulins 432
One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation 431
White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths 431
13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. 430
Skills and requirements of a transplant hepatologist: board certification of the Italian Association for the Study of the Liver (AISF) 430
Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease 428
Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells 428
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C 428
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 428
The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. 428
Qualitative patterns of biliary bile acids affect cyclosporine intestinal absorption in liver transplant recipients 427
International comparison of liver transplant programmes: differences in indications, donor and recipient selection and outcome between Italy and UK 427
Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis 426
Totale 47.664
Salva come PNG Salva come JPEG
Categoria #
all - tutte 230.229
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 230.229
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.774 122 278 162 157 64 361 120 113 269 247 109 772
2022/20233.203 376 233 124 345 252 743 271 185 300 28 284 62
2023/2024862 134 21 85 20 91 215 14 22 11 23 7 219
2024/20256.080 187 1.289 617 335 114 475 295 228 541 386 865 748
2025/20269.750 744 431 1.022 907 842 549 1.243 1.442 990 812 438 330
2026/202717 17 0 0 0 0 0 0 0 0 0 0 0
Totale 109.183